Our growing understanding of human genetics has the potential to bring many benefits for health; however, there are widespread public concerns about the potential for eugenics and discrimination. Meanwhile, there are commercial imperatives to develop new tests, technologies and pharmaceuticals. In this uncertain era, effective regulation and balanced ethical debate is vital so that societies can maximise the benefits and avoid the dangers of genetic knowledge.

This event explores international perspectives on both clinical and commercial exploitation of genetic knowledge and the regulation of science. Topics covered include:

• effective regulation: the UK Human Genetics Commission and the Human Fertilisation and Embryology Authority
• commercialisation: IPR, public/private relationships and patenting
• choices and values: screening, sex selection, religious and cultural diversity
• communications: engagement, accountability and participation in debates on genetics.

Participant profile
The programme is of interest to those involved in commercial and clinical developments based on new genetic knowledge; clinicians and scientists, investors, entrepreneurs, regulators, policy makers, lawyers and ethicists, and those who contribute to the public debate on genetic science (journalists, broadcasters, science communicators).